TFX — Teleflex Incorporated

Is TFX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Instruments & Supplies

Overbought As of November 17, 2026

Teleflex Incorporated (TFX) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $159.60. The rating moved from Neutral to Overbought on November 16, 2026.

See all overbought Healthcare stocks →

AI analysis

Teleflex Incorporated (TFX) benefits from a diversified, procedure-driven product mix and recurring consumable revenues that support steady cash generation and margin resilience. Expanding addressable markets tied to broader adoption of robotic-assisted and general surgery procedures provide a meaningful growth runway, while balance sheet flexibility supports capital returns and selective M&A. Near-term performance will be driven by elective procedure volumes, execution on product rollouts, and the firm's ability to mitigate input cost pressures; regulatory or reimbursement shifts and intensified competition remain the primary downside risks.

Key factors

  • Recurring, procedure-driven revenue mix with high consumable attach rates supports cash flow visibility and margin resilience
  • Exposure to expanding addressable market from broader adoption of robotic-assisted and general surgery procedures increases long‑term instrument/consumable demand
  • Diversified product portfolio across airway management, vascular access and specialty procedural devices reduces single-product concentration risk
  • Historically strong free cash flow and balance sheet flexibility enable continued share repurchases, dividends and strategic M&A to drive growth
  • Stability of elective procedure volumes and defensive characteristics versus pure cyclical medical device peers provide near-term demand support
  • Operational pricing power to offset some input cost inflation, supporting margin preservation

Risks

  • Competitive pressure from larger OEMs and new entrants in surgical robotics and disposable instrument markets could compress pricing and share
  • Healthcare reimbursement and regulatory changes (including Medicare program integrity actions) that alter hospital economics or procedure mix
  • Procedure volume sensitivity to macro weakness or regional healthcare policy shifts could reduce consumable demand
  • Supply chain disruptions or component shortages that inflate costs or constrain shipment cadence
  • Execution risk on R&D commercialization, product launches and any acquisition integrations
  • Foreign exchange and international exposure impacting reported revenue and margins

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for TFX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.